AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

QUEBEC CITY, Aug. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), its partner and licensee for perifosi...

Patton Medical Devices Partners With Unomedical to Develop and Market the i-port Advance(TM) Injection Port for People Taking Multiple Daily Injections

AUSTIN, Texas, July 27 /PRNewswire/ -- Patton Medical Devices, manufacturer of the i-port(R) and a leader of injection port therapy, announced today that they have entered into a partnership agreement with Unomedical, a leading manufacturer of single use medical devices used in th...

MEDS World, LLC Provides Multiple Environments with Designed Solutions - Wherever People Congregate, MEDS Odor Elimination Solutions Offer Eco-Friendly, Odor-Free Air

In 2008, Bruce Hecht and Chase Walker formed MEDS World, LLC, launching innovative odor elimination, exterior plastic trim and headlight restoration products to the Automotive, RV and Marine industries. Bruce and Chase have combined over fifty years of management experiences, in a myriad of indus...

iCardiac Selected for Multiple Cardiac Safety Studies

Continues Market Leadership in Highly Automated QT(sm) Evaluation and Helps Sponsors Avoid False Positives Rochester, NY (PRWEB) June 15, 2009 -- iCardiac Technologies, Inc., a leader in advanced cardiac safety biomarker development and automated QT analysis, announced ...

Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association

SOUTH SAN FRANCISCO, Calif., June 8 /PRNewswire/ -- Proteolix, Inc. today announced data from ongoing Phase 2 and Phase 1b clinical trials of carfilzomib for the treatment of multiple myeloma at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany. Carfilzomib is the ...

Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy

NEW BRUNSWICK, N.J., May 27 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT ) announced today that Richard Dondero, Vice President of Research and Development, will be presenting pre-clinical data from Senesco's multiple myeloma studies at...

Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting

HUNTINGTON BEACH, California and AMSTERDAM, May 21 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia, the University of California San Francisco and the Netherlands Cancer Institute will present data from multiple s...

BioMS Medical's pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board

Toronto Stock Exchange Symbol: MS EDMONTON, April 21 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's pivotal phase III MAESTRO-01...

Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models

- Data on novel pro-apoptotic agent presented at the 100th Annual Meeting of the American Association for Cancer Research - - University of Pennsylvania data on chemotherapy resistance patterns in neuroblastoma cell lines, highlighting AT-101's inhibition of Mcl-1, also presented - MA...

BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board

Toronto Stock Exchange Symbol: MS EDMONTON, April 14 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAEST...

Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis

CHARLOTTESVILLE, Virginia, April 2 /PRNewswire/ -- Biovista Inc. today announced that BVA-101, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-101, an existing drug that ...

First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated

Findings Support Development for Chronic Pain Indications LA JOLLA, Calif., Feb. 11 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced that oral administration of NGX426, an AMPA/kainate-type glutamate receptor antagonist, was safe and well-tolerated in healthy m...

BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis

Toronto Stock Exchange Symbol: MS EDMONTON, Jan. 30 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced results from MINDSET-01, an exploratory phase II clinical trial evaluating dirucotide in patients with r...

International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"

BIRMINGHAM, England, January 28 /PRNewswire/ -- The Binding Site Limited ("The Binding Site" or the "Company"), a privately-owned specialist U.K. diagnostics company, today announces the publication of the first international guidelines recommending first-line use of Freelite(TM) in the diagno...

Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology

SOUTH SAN FRANCISCO, Calif., Dec. 9 /PRNewswire/ -- Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma. Carfilzomib is...

EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma

ROCKVILLE, Md., Dec. 9 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has initiated a Phase 1 study of ENMD-2076 in refractory multiple myelom...

Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium

REDWOOD CITY, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX ) today announced that the company will present results from four studies at the 31st Annual San Antonio Breast Cancer Symposium, taking place December 10-14, 2008, at the Henry B. Gonzalez Convention Cente...

Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference

Clinical evidence continues to build for the company's key technologies PRINCETON, N.J., Oct. 22 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a company specializing in advanced wound care, today announced that eleven clinical posters focusing on its new technologi...

TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel

LA JOLLA, Calif., Oct. 20 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced it initiated dosing of the first cohort of subjects in a Phase I multiple dose clinical trial of NGX426, the oral prodrug of its most advanced product candidate, tezampanel. The trial is d...

Senesco's Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics'

NEW BRUNSWICK, N.J., Oct. 20 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US: SNT) announced today that Catherine Taylor, one of the Company's funded researchers, will be presenting her findings related to Senesco's preclinical multiple myel...

Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug

BOULDER, Colo., Oct. 15 /PRNewswire/ -- Bolder BioTechnology, Inc. announced today that it has been awarded a $1.6 million Phase II Continuing Renewal Small Business Innovation Research (SBIR) grant, entitled "Long-Acting Beta Interferon for Multiple Sclerosis", from the National Institute of ...

Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions

SOUTHAMPTON, Pa., Oct. 9 /PRNewswire-FirstCall/ -- Environmental Tectonics Corporation's (Amex: ETC ) ("ETC" or the "Company") BioMedical Division today announced the sale of three (3) additional BARA-MED(R) XD Monoplace Hyperbaric Chambers to Comprehensive Healthcare Solutions, Inc. Compre...

BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board

Toronto Stock Exchange Symbol: MS EDMONTON, Oct. 6 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of ...

BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board

Toronto Stock Exchange Symbol: MS EDMONTON, Oct. 3 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTR...

Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting

-- Company Also Announces Participation in Upcoming Investor Conferences in October -- SAN DIEGO, Sept 29 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obesity and other central nervou...

Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908

- Results Expected in Fourth Quarter of 2008 - MONTVALE, N.J., Sept. 26 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced that it has completed its Phase 1 multiple ascending dose study of R4996/MEM 63908 in healthy volunteers. The multiple ascending dos...

Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers

SOUTHAMPTON, Pa., Sept. 23 /PRNewswire-FirstCall/ -- Environmental Tectonics Corporation's (Amex: ETC ) ("ETC" or the "Company") BioMedical Division today announced the sale and placement of two BARA-MED(R) XD Monoplace Hyperbaric Chambers at Christus Spohn, Shoreline Facility. The Shoreline ...

Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis

CAMBRIDGE, Mass., Sept. 16 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced today that Dr. Joseph Kovalchin will make a poster presentation titled "Evidence of Specific T-cell Priming from the First-in-Man Single Ascending Dose Study of Peptide Copolymer PI-23...

BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA

Toronto Stock Exchange Symbol: MS EDMONTON, Sept. 4 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for...

Expert Neurology Panel Weighs Impact of New Reports of PML in Multiple Sclerosis Patients on Tysabri

SCOTTSDALE, Ariz., Aug. 20 /PRNewswire/ -- MedPredict, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for multiple sclerosis (MS) thera...

BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis

Toronto Stock Exchange Symbol: MS - Milestone triggers $10 million payment from Eli Lilly and Company - EDMONTON, Aug. 13 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Drug Safety ...

BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial

Toronto Stock Exchange Symbol: MS EDMONTON, Aug. 1 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it has completed patient recruitment in its phase III clinical trial of MBP8298 (dirucotide) for th...

BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board

Toronto Stock Exchange Symbol: MS EDMONTON, July 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of...

Environmental Tectonics Corporation's BioMedical Systems Division Awarded Contract for Multiple Monoplace Chambers

SOUTHAMPTON, Pa., June 10 /PRNewswire-FirstCall/ -- Environmental Tectonics Corporation's (Amex: ETC ) ("ETC" or the "Company") BioMedical Systems division today announced the sale of seven (7) BARA-MED(R) XD Monoplace Hyperbaric Chambers to Med One Capital for placement at four (4) facilitie...

Bionovo Develops a High Throughput LC-MS/MS Method for Simultaneous Quantification of Multiple Bioactive Compounds

-Results Will be Presented at the American Society for Mass Spectrometry 56th ASMS Conference in Denver, June 2-5, 2008- EMERYVILLE, Calif., June 5 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI ) today announced that it has developed a novel analytical 2-dimensional liquid c...

Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017

Overall Market Growth Will be Driven by Launch of Nine Emerging Therapies, Including Five Oral Agents, According to a New Report from Decision Resources WALTHAM, Mass., May 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory fir...

New Liko Multiple Purpose Lifting Straps Facilitate Patient Care Tasks

FRANKLIN, Mass., May 27 /PRNewswire/ -- Liko, a leading supplier of patient lifting equipment, has introduced the Multi-Strap(TM) product line, a series of innovative multi-purpose handling straps designed to assist caregivers with a variety of patient care tasks. The new the Multi-Strap pro...

BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board

Toronto Stock Exchange Symbol: MS EDMONTON, May 27 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MIN...

Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Multiple Myeloma at AACR Annual Meeting

CALGARY, April 15 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that an oral presentation by Dr. Chandini Thirukkumaran of the Tom Baker Cancer Centre, Calgary, entitled "Targeting Multiple Myeloma with Oncolytic Viral Therapy" was presented today at the A...

BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board

Toronto Stock Exchange Symbol: MS EDMONTON, April 15 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) has reviewed data from the C...